PubMed Health⌕ Search

Biomedical subjects

G Scambia

Publications and source records attributed to G Scambia.

At least 307 records · Page 17Linked to original sources

Squamous cervical cancer at stage IB and II: a ten years experience, analysis of 231 cases.

The authors have reviewed their experience on treatment of carcinoma of the uterine cervix at stage I and II, with a special regard for prognostic factors. The best survival results at 7 years for patients at stage I B and II A were obtained with integrated treatments, while for stage II B patient no treatment proved to be really effective. Lymphnodal infiltration, increasing with the stage, was the most important prognostic factor, but stage must always be taken into account, especially in N- patients. Some considerations are then made on the importance of prognostic factors such as lymphnode status and tumour volume, in order to improve the survival results.

Carcinoma, Squamous Cell↗

Estrogen responsive creatine kinase in human breast cancer cells.

The brain type (BB) isoenzyme of creatine kinase (CK) is a very sensitive marker of estrogen action in rat uterus and in experimental mammary tumors. In order to detect useful markers for estrogen dependent human breast cancer cell proliferation we measured CK levels and isoenzyme composition in the CG5 cells, an estrogen supersensitive variant of the MCF-7 human breast cancer cell line. Under basal conditions, CK-BB accounted for 10%-15% of total enzymatic activity, while the MM isoenzyme represented the overwhelming component. In cells cultured in the presence of 5% charcoal-treated fetal calf serum, physiological concentrations (0.1-1 nM) of estradiol increased CK-BB levels in a dose- and time-related fashion. The effect was specific for estrogens and was prevented by antiestrogens. Our results show that CK-BB is estrogen regulated in the CG5 cells and suggest a possible role for this enzyme as an additional marker of the hormonal responsiveness of breast cancer.

Breast Neoplasms↗

Effect of tamoxifen on steroid hormone receptors and creatine kinase activity in human endometrial carcinoma.

Estrogen receptor (ER), progesterone receptor (PR) and creatine kinase (CK) were measured in cancerous tissue from 29 post-menopausal patients with endometrial carcinoma under basal conditions and after a short course of tamoxifen treatment. ER and PR were detected in nearly all tumors. CK was detected in all of the tumors examined. After tamoxifen, PR and CK increased simultaneously in 26% of cases, while they were either enhanced, decreased or unmodified in the remainder. No correlation could be found between increase of PR and tumor differentiation. CK, however, was enhanced only in the more differentiated cancers. These results indicate that only a percentage of endometrial cancers are responsive to tamoxifen. It is hypothesized that patients bearing these tumors are those likely to benefit from endocrine therapy.

Cell Transformation, Neoplastic↗

Elevated plasma levels of beta-thromboglobulin in breast cancer.

Beta-thromboglobulin, a platelet-specific protein secreted into the plasma during the release reaction, was measured in 73 women with breast cancer, 10 women with dysplastic disease and 30 healthy female control subjects. 73% of patients with primary operable breast cancer and 65% with metastatic disease had levels above 40 ng/ml (control range 11-38 ng/ml). Among 2-6 months' postoperative patients without evidence of disease at the time of sampling, beta-thromboglobulin was raised in 75% of patients with nodal involvement and in 28% of patients without nodal involvement. Only 1 of 10 patients with benign disease showed abnormal beta-thromboglobulin concentration. Our results show that in a high percentage of breast cancer patients a state of ongoing in vivo platelet activation may be present. Furthermore, beta-thromboglobulin can be regarded as a potential tumor marker in breast cancer.

Adult↗

Early hemostatic disorders in patients with gynecologic tumors.

One hundred and seventeen female subjects were studied: 23 patients with cervical carcinoma; 25 with endometrial carcinoma; 29 with benign uterine diseases; 14 with ovarian carcinoma; 26 patients with benign ovarian tumors. These patients, together with 25 healthy female control subjects, underwent several coagulation tests including Beta-Thromboglobulin (Beta-TG) and Platelet Factor 4 (PF4) plasma levels. Among all Beta-TG and PF4 exhibited the most interesting results. They were increased in four groups of patients: those with malignant 92.2% (13/14) and benign 50% (13/26) ovarian tumors and those with endometrial 64% (16/25) and cervical carcinoma 69.5% (16/23). Our study showed a high incidence of abnormalities of Beta-TG and PF4, early signs of hemostatic disorders, in gynecological malignancies especially in ovarian carcinoma. These data suggest a possible value of these tests as tumor-markers and in order to detect the patients who develop thrombo-embolic accidents.

Adult↗

Evaluation of circulating immune complexes (C.I.C.) in endometrial cancer.

We evaluated the presence of CIC in 32 patients with histological proven cancer of endometrium: 23 stage IA or IB (i.e. localized disease), 9 in stage II or III (i.e. advanced disease). The determination of CIC was done at the time of the diagnosis before the patients underwent any surgical or medical therapy. The presence of CIC was demonstrated in 17% (4/23) of the patients with localized disease and in 56% (9/9) of the patients with more advanced disease. Our findings indicate that the presence of CIC is higher in patients with advanced endometrial carcinoma (stage II, III), than in those suffering of a more limited disease (stage IA, IB) and this seems could be consistent with a possible role in modulating the immune response against tumour itself.

Adult↗

Sex steroid receptors in normal and malignant human vulvar tissue.

Receptors for estrogens, progesterone and androgens were assayed in 6 specimens of normal vulvar tissue and in 9 specimens of carcinomatous vulvar tissue. These receptors were not always present in all specimens examined. In both normal and carcinomatous tissues receptor concentration was highly variable. Malignant tissues did not show significant changes in values compared to normal tissue.

Aged↗

Effects of intra-amniotic isoxsuprine on amino acid placental transfer in rats.

Direct administration of isoxsuprine to the rat fetus increases placental transfer of 35S-methionine and this increase is statistically significant on day 17 as compared with intraperitoneal administration and controls (p less than 0.01; p less than 0.05). In contrast, no statistically significant differences were found between the groups on day 16.

Amino Acids↗

Malignant fibrous histiocytoma. Report of a case and review of the literature.

Malignant Fibrous Histiocytoma is a sarcoma characterized by two different principal cell types, which has its origin in mesenchymal undifferentiated clones. So it must be included in the differential diagnosis of the very rare primary breast tumors with stromal origin. The review of available literature allows us to define the histopathological and biological peculiarities of this kind of tumor and it confirms the extreme malignity and rarity of the case we observed.

Breast Neoplasms↗

A monoclonal antibody (AB/3) reactive with human breast cancer.

Monoclonal antibody AB/3 was produced from a fusion of spleen cells of a human breast cancer cell-primed BALB/c mouse with the murine myeloma cell line P3-NS1-Ag4-1. The antibody reacted strongly with the plasma membrane of human breast cancer cells. Tissue sections of both malignant and benign human mammary carcinomas and tumors of non-breast origin as well as apparently normal tissues were tested with immunoperoxidase. Ninety-six of 124 (77%) primary human breast cancers, 12 of 14 (86%) metastatic breast lesions, and 12 of 44 (27%) benign breast lesions reacted positively. Little or no appreciable reactivity was observed with apparently normal human tissues and carcinomas of non-breast origin, with the exception of colon carcinoma. Antibody AB/3 did not immunoprecipitate any identifiable protein from radiolabeled extracts of the immunizing cell line.

Animals↗

Elevated serum levels of creatine kinase BB in breast cancer.

Creatine kinase BB serum levels were evaluated by radioimmunoassay in patients with benign or malignant breast pathology. Elevated enzyme levels were observed in 6 out of 20 (30%) patients with primary breast cancer. After surgery the levels fell to normal values only in patients without nodal involvement. Six out of 28 (21%) patients with benign breast lesions and 4 out of 38 (13%) patients with metastatic breast cancer also showed increased levels of the enzyme. Most of the patients with high creatine kinase BB serum levels were found to have estrogen and progesterone receptor-positive tumors. These findings suggest that creatine kinase BB can barely be considered a marker of malignancy in breast pathology, but rather an indicator of hormone dependency in breast cancer.

Adult↗

Estrogen stimulates cell proliferation and the increase of a 52,000 dalton glycoprotein in human breast cancer cells.

In an estrogen supersensitive variant of the MCF-7 cell line, CG-5, estrogen was found to stimulate the labelling of a glycoprotein released into the culture medium which has the same electrophoretic migration pattern as that previously reported in MCF-7 cells (Biochem. Biophys. Res. Commun., 90: 410-416, 1979). To test the possibility that the 52 K is a marker of estrogen-dependent breast cancer cell proliferation, we have correlated the effect of estrogen and antiestrogen on protein labelling and cell proliferation under different experimental conditions. In cells cultured in the presence of 5% charcoal-treated fetal calf serum, physiological concentrations (0.1-1 nM) of estradiol stimulated in a dose- and time-related fashion both 52 K labelling and cell proliferation. However at high concentrations (10-100 nM) estrogen decreased 52 K labelling while it still stimulated cell proliferation. Concentrations of the tamoxifen derivative, 4-hydroxytamoxifen, which effectively prevented estrogen-stimulated cell proliferation also blocked estrogen-stimulated increase of 52 K labelling. Time-course experiments suggest that the estrogen-stimulated increase of 52 K labelling (detectable after 22 h of hormone exposure) precedes the effect of cell proliferation (detectable after 3 days of hormone exposure). In cells cultured under serum-free conditions there was no effect of estradiol at any of the concentrations and times used on either 52 K labelling or cell proliferation.

Breast Neoplasms↗

Creatine kinase BB in normal, hyperplastic and neoplastic endometrium.

We measured creatine kinase BB activity in normal, hyperplastic and neoplastic endometrium. Creatine kinase BB levels were higher in secretory than in proliferative endometrium. High levels were also found in hyperplastic tissue. In endometrial cancer creatine kinase BB activity was higher in well differentiated than in poorly differentiated tumors.

Creatine Kinase↗

Estrogen-responsive creatine-kinase in the reticulo-epithelial cells of rat thymus.

We have evaluated the presence of the so-called "estrogen-induced protein" (IP) in the thymus of immature rat. IP is one of the earliest proteins synthesized in response to estrogen in rat uterus and has recently been identified as the BB-isozyme of creatine-kinase (J. Biol. Chem. 256 (1981) 5741). Estrogen-exposed tissues were labelled with [35S]methionine and the soluble proteins separated by SDS-polyacrylamide gel electrophoresis followed by fluorography. It was observed that estrogen stimulated the labelling of a thymic protein with electrophoretic mobility identical to that of uterine IP. The effect was dose-related and specific for estrogen receptor ligands. Thymic IP, like that of the uterus, was immunoprecipitated equally well by either anti-IP antiserum from rat uterus or anti-BB-creatine-kinase antiserum from rat brain. After purification by ion-exchange and affinity chromatography, there was a parallel increase in the extent of recovery of IP and BB-creatine-kinase activity in both the thymus and the uterus. Using the immunohistochemical peroxidase-antiperoxidase method with anti-IP serum, the immune-reaction product was localized in a few cells identified as reticulo-epithelial cells. The thymocytes were always free of any reaction product. These data demonstrate that the reticulo-epithelial cells of rat thymus are a target for estrogens.

Animals↗

Steroid-induced proteins in human endometrium.

The synthesis of soluble proteins in human endometria at various phases of menstrual cycle was evaluated by polyacrylamide gel electrophoresis of [35S]methionine-labeled proteins. Densitometric analysis of the gels revealed alterations in the rate of synthesis of single protein bands throughout the cycle. Administration of conjugated estrogens (Premarin) to women undergoing hysterectomy, or exposure, in vitro, of the endometrial tissue to 17 beta-estradiol produced an increased incorporation of [35S]methionine into a specific protein which migrated on SDS-polyacrylamide gels at a molecular weight of about 55 000. Induction of this protein was observed only in those endometria showing a secretory histological appearance. The protein was resolved into at least 2 different spots in two-dimensional gel electrophoresis. An increase in the rate of synthesis of another endometrial protein with an apparent molecular weight of 51 000 was observed in tissues exposed in vitro to medroxyprogesterone acetate. These steroid-induced proteins may be a useful marker for studying hormone action in both normal and neoplastic endometria.

Electrophoresis, Polyacrylamide Gel↗

A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.

The treatment of recurrent or progressive ovarian cancer has limited therapeutic potential. The clinical outcome of second-line therapy largely depends on the potential chemo-sensitivity of the tumor expressed during up-front chemotherapy, as well as on the treatment-free interval from the last course of cytotoxic therapy. However, the identification of agents such as tamoxifen (TAM) at nontoxic doses, able to act synergistically with standard chemotherapy, may be useful to overcome resistance. Fifty patients with recurrent or progressive ovarian cancer following platinum (P)-based chemotherapy (28 platinum-resistant and 22 platinum-sensitive) entered a Phase II trial to evaluate the efficacy and toxicity of P re-challenge with the addition of TAM as a chemotherapy response modulator. The choice of the P compound (100 mg/m2 cisplatin or 400 mg/m2 carboplatin, q3 weeks) was made on the basis of the prior total cisplatin dose and the presence of neurotoxicity. TAM was administered at the doses of 80 mg/day for 30 days followed by 40 mg/day for the remaining period of treatment. Toxicity consisted mainly of mild to moderate nausea and vomiting (76%), peripheral neuropathy (43%), nephrotoxicity (4%), anemia (16%), leukopenia (58%) and thrombocytopenia (16%). The overall response to the P-TAM combination was 50% (complete response 30%; partial response 20%) with a median duration of 8.5 months (3-42). Sixty-four percent of the P-sensitive and 39% of the P-resistant patients responded (59% and 33%, respectively, for those bearing measurable disease). The overall median survival was 23 (3-48) and 19 months for the patients with measurable disease (20 months for the P-resistant group). This phase II trial confirmed the activity for a re-challenge employing a P compound and TAM in clinically defined P-resistant ovarian cancer patients. The mild toxicity profile and the relatively low cost of the treatment render further investigations on the P-TAM regimen worthwhile.

Adenocarcinoma, Clear Cell↗